Abstract 5071
Background
Oropharyngeal squamous cell carcinoma (OPSC) continues to increase in incidence with human papillomavirus (HPV) infection. Despite the good overall prognosis, it needs to assess the risk of not only survival, but also the risk of local, regional, or distant treatment failure to guide de-intensification regimens. This study aimed to investigate the expression of estrogen receptor (ER) and programmed cell death-ligand 1 (PD-L1) proteins according to the status of HPV infection and their prognostic implication in OPSCC patients.
Methods
Consecutive 80 patients diagnosed with OPSCC with surgical treatment from 2004 to 2017 were included. Immunohistochemistry for ER and PD-L1 was performed formalin-fixed, paraffin embedded tissues. HPV status assessed with p16 immunohistochemistry and HPV DNA testing.
Results
ER and PD-L1 expression were observed in 37.5% (30/80) and 60% (48/80), respectively. Both ER and PD-L1 protein expression were higher in HPV-positive OPSCC than in HPV-negative subgroup (47.5% vs. 9.5% for ER, 66.1% vs. 42.9% for PD-L1). There was no significant association between ER and PD-L1 expression (correlation coefficient: 0.105, p > 0.05). Using Kaplan-Meier curves, PD-L1 expression was associated with longer recurrence-free duration (p = 0.013), whereas ER expression was associated with prolonged overall survival (p = 0.043). In subgroup analysis, PD-L1 expression was found to be an independent excellent prognostic factor for recurrence-free duration in HPV-positive OPSCC (p = 0.002, HR = 0.085 [0.018-0.399]). ER expression also tended to be associated with longer overall survival in the HPV-positive OPSCC subgroup, but no statistical significance was observed. In HPV-negative subgroup, both ER and PD-L1 expression were not associated with any clinicopathologic factor nor survival.
Conclusions
ER and PD-L1 expression can be complementary prognostic factors in HPV-positive OPSCC. It may allow us to investigate the independent role of anti-hormone receptors and the tumor microenvironment in the treatment of OPSCC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5031 - Sarcoidosis-Like Reaction Mimics Progression in patients treated with immune checkpoint inhibitors
Presenter: Sophie Hans
Session: Poster Display session 3
Resources:
Abstract
5650 - Tissue-based activation of mucosal-associated invariant T (MAIT) cells in combination ipilimumab and nivolumab checkpoint inhibitor (CI) colitis.
Presenter: Sarah Sasson
Session: Poster Display session 3
Resources:
Abstract
5944 - Significance of severe immune-related adverse effects (irAE) on patients with advanced tumors treated with immune checkpoint inhibitors being admitted for secondary toxicity: Clinical relevance and next steps
Presenter: Leyre Zubiri
Session: Poster Display session 3
Resources:
Abstract
5989 - Implementation of a dedicated immuno-oncology toxicity service reduces the acute impact of immune-related adverse events
Presenter: Anna Olsson-Brown
Session: Poster Display session 3
Resources:
Abstract
3267 - Cardiotoxic and pro-inflammatory effects induced by the association of immune checkpoint inhibitor Pembrolizumab and Trastuzumab in preclinical models
Presenter: Nicola Maurea
Session: Poster Display session 3
Resources:
Abstract
3417 - Interstitial lung disease associated with immune-checkpoint inhibitors in malignant diseases
Presenter: Akira Yamagata
Session: Poster Display session 3
Resources:
Abstract
2071 - A Phase 1 Study of Intraperitoneal MCY-M11 Anti-Mesothelin CAR for Women with Platinum Resistant High Grade Serous Adenocarcinoma of the Ovary, Primary Peritoneum, or Fallopian Tube, or Subjects with Peritoneal Mesothelioma with Recurrence after Prior Chemotherapy
Presenter: Christina Annunziata
Session: Poster Display session 3
Resources:
Abstract
4935 - Trial in progress: First-in-human study of a novel anti-NY-ESO-1–anti-CD3, TCR-based bispecific (IMCnyeso) as monotherapy in NY-ESO-1/LAGE-1A-positive advanced solid tumors (IMCnyeso-101)
Presenter: Juanita Lopez
Session: Poster Display session 3
Resources:
Abstract
5613 - Nimotuzumab-Cisplatin-Radiation versus Cisplatin-Radiation in HPV negative oropharyngeal cancer
Presenter: Kumar Prabhash
Session: Poster Display session 3
Resources:
Abstract
2576 - Interim analysis of a single arm phase 2 study of adjuvant nivolumab after salvage resection in head and neck squamous cell carcinoma patients previously treated with definitive therapy.
Presenter: Trisha Wise-draper
Session: Poster Display session 3
Resources:
Abstract